| Host: |
Rabbit |
| Applications: |
WB/IHC/IF/ELISA |
| Reactivity: |
Human/Mouse/Rat |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Rabbit polyclonal antibody anti-Phospho-CCAAT/enhancer-binding protein beta-Thr235 (201-250 aa) is suitable for use in Western Blot, Immunohistochemistry, Immunofluorescence and ELISA research applications. |
| Clonality: |
Polyclonal |
| Conjugation: |
Unconjugated |
| Isotype: |
IgG |
| Formulation: |
Liquid in PBS containing 50% Glycerol, 0.5% BSA and 0.02% Sodium Azide. |
| Purification: |
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration: |
1 mg/mL |
| Dilution Range: |
WB 1:500-1:2000IHC 1:100-1:300IF 1:200-1:1000ELISA 1:10000 |
| Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Gene Symbol: |
CEBPB |
| Gene ID: |
1051 |
| Uniprot ID: |
CEBPB_HUMAN |
| Immunogen Region: |
201-250 aa |
| Specificity: |
Phospho-C/EBP Beta (T235) Polyclonal Antibody detects endogenous levels of C/EBP Beta protein only when phosphorylated at T235. |
| Immunogen: |
The antiserum was produced against synthesized peptide derived from the human C/EBP-beta around the phosphorylation site of Thr235/188 at the amino acid range 201-250 |
| Post Translational Modifications | Methylated. Methylation at Arg-3 by CARM1 and at Lys-43 by EHMT2 inhibit transactivation activity. Methylation is probably inhibited by phosphorylation at Thr-235. Sumoylated by polymeric chains of SUMO2 or SUMO3. Sumoylation at Lys-174 is required for inhibition of T-cells proliferation. In adipocytes, sumoylation at Lys-174 by PIAS1 leads to ubiquitination and subsequent proteasomal degradation. Desumoylated by SENP2, which abolishes ubiquitination and stabilizes protein levels. Ubiquitinated, leading to proteasomal degradation. Phosphorylated at Thr-235 by MAPK and CDK2, serves to prime phosphorylation at Thr-226 and Ser-231 by GSK3B and acquire DNA-binding as well as transactivation activities, required to induce adipogenesis. MAPK and CDK2 act sequentially to maintain Thr-235 in the primed phosphorylated state during mitotical cloning expansion and thereby progression of terminal differentiation. Phosphorylation at Thr-266 enhances transactivation activity. Phosphorylation at Ser-325 in response to calcium increases transactivation activity. Phosphorylated at Thr-235 by RPS6KA1. O-glycosylated, glycosylation at Ser-227 and Ser-228 prevents phosphorylation on Thr-235, Ser-231 and Thr-226 and DNA binding activity which delays the adipocyte differentiation program. Acetylated. Acetylation at Lys-43 is an important and dynamic regulatory event that contributes to its ability to transactivate target genes, including those associated with adipogenesis and adipocyte function. Deacetylation by HDAC1 represses its transactivation activity. Acetylated by KAT2A and KAT2B within a cluster of lysine residues between amino acids 129-133, this acetylation is strongly induced by glucocorticoid treatment and enhances transactivation activity. |
| Function | Important transcription factor regulating the expression of genes involved in immune and inflammatory responses. Also plays a significant role in adipogenesis, as well as in the gluconeogenic pathway, liver regeneration, and hematopoiesis. The consensus recognition site is 5'-TTGNNGNAATG-3'. Its functional capacity is governed by protein interactions and post-translational protein modifications. During early embryogenesis, plays essential and redundant roles with CEBPA. Has a promitotic effect on many cell types such as hepatocytes and adipocytes but has an antiproliferative effect on T-cells by repressing MYC expression, facilitating differentiation along the T-helper 2 lineage. Binds to regulatory regions of several acute-phase and cytokines genes and plays a role in the regulation of acute-phase reaction and inflammation. Also plays a role in intracellular bacteria killing. During adipogenesis, is rapidly expressed and, after activation by phosphorylation, induces CEBPA and PPARG, which turn on the series of adipocyte genes that give rise to the adipocyte phenotype. The delayed transactivation of the CEBPA and PPARG genes by CEBPB appears necessary to allow mitotic clonal expansion and thereby progression of terminal differentiation. Essential for female reproduction because of a critical role in ovarian follicle development. Restricts osteoclastogenesis: together with NFE2L1.represses expression of DSPP during odontoblast differentiation. Isoform 2: Essential for gene expression induction in activated macrophages. Plays a major role in immune responses such as CD4(+) T-cell response, granuloma formation and endotoxin shock. Not essential for intracellular bacteria killing. Isoform 3: Acts as a dominant negative through heterodimerization with isoform 2. Promotes osteoblast differentiation and osteoclastogenesis. |
| Protein Name | Ccaat/Enhancer-Binding Protein BetaC/Ebp BetaLiver Activator ProteinLapLiver-Enriched Inhibitory ProteinLipNuclear Factor Nf-Il6Transcription Factor 5Tcf-5 |
| Database Links | Reactome: R-HSA-2559582Reactome: R-HSA-380994Reactome: R-HSA-381340Reactome: R-HSA-8853884Reactome: R-HSA-9616222Reactome: R-HSA-9633012Reactome: R-HSA-9648895Reactome: R-HSA-9725371 |
| Cellular Localisation | NucleusCytoplasmTranslocates To The Nucleus When Phosphorylated At Ser-288In T-Cells When Sumoylated Drawn To Pericentric Heterochromatin Thereby Allowing Proliferation |
| Alternative Antibody Names | Anti-Ccaat/Enhancer-Binding Protein Beta antibodyAnti-C/Ebp Beta antibodyAnti-Liver Activator Protein antibodyAnti-Lap antibodyAnti-Liver-Enriched Inhibitory Protein antibodyAnti-Lip antibodyAnti-Nuclear Factor Nf-Il6 antibodyAnti-Transcription Factor 5 antibodyAnti-Tcf-5 antibodyAnti-CEBPB antibodyAnti-TCF5 antibodyAnti-PP9092 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
